The GEMSTONE-303 study demonstrated that sugemalimab plus CAPOX chemotherapy significantly improved both PFS and OS compared to placebo plus CAPOX in patients with unresectable locally advanced or metastatic GC/GEJC PD-L1 CPS ≥ 5, establishing it as a new standard of care for first-line GC therapy. Here, CD274 is linked to gastric cancer.